Vertex Pharmaceuticals Incorporated P/E Ratio 2008–2025
Vertex Pharmaceuticals Incorporated reported 29.59 of price-to-earnings ratio for fiscal 2025. That was 1.0% higher than fiscal 2023. Compared with fiscal 2020, the change was +28.8%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 29.59 | — |
| FY 2024 | — | — |
| FY 2023 | 29.29 | +30.0% |
| FY 2022 | 22.53 | -7.6% |
| FY 2021 | 24.37 | +6.1% |
| FY 2020 | 22.97 | -52.7% |
| FY 2019 | 48.55 | +137.0% |
| FY 2018 | 20.48 | -85.8% |
| FY 2017 | 144.10 | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | 237.21 | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
| FY 2008 | — | — |
Source: Vertex Pharmaceuticals Incorporated SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open VRTX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Vertex Pharmaceuticals Incorporated reported 29.59 of price-to-earnings ratio for fiscal 2025. That was 1.0% higher than fiscal 2023. Compared with fiscal 2020, the change was +28.8%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Vertex Pharmaceuticals Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeVertex Pharmaceuticals Incorporated — frequently asked questions
What is Vertex Pharmaceuticals Incorporated's price-to-earnings ratio?
Vertex Pharmaceuticals Incorporated (VRTX) reported price-to-earnings ratio of 29.59 for fiscal year 2025, per its SEC filings.
How has Vertex Pharmaceuticals Incorporated's price-to-earnings ratio changed over time?
Between fiscal 2008 and 2025, VRTX's price-to-earnings ratio declined at roughly 11.5% per year (compound annual rate), from 237.21 to 29.59.
Where does this data come from?
Figures are computed from Vertex Pharmaceuticals Incorporated's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More VRTX financial history
Full VRTX fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →